多替拉韦

Description

Dolutegravir · CAS 1051375-16-6 · C20H19F2N3O5. UNII DKO1W9H7M1. Melting Point: 190-193ºC; LogP: 2.2; Dissociation Constants: 8.2.

Identification

CAS Registry Number	1051375-16-6
PubChem CID	54726191
Molecular formula	C20H19F2N3O5
IUPAC name	(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
UNII (FDA)	DKO1W9H7M1

Computed Descriptors

Molecular Weight	419.4
XLogP3	2.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	3
Exact Mass	419.12927704
Monoisotopic Mass	419.12927704
Topological Polar Surface Area	99.2
Heavy Atom Count	30
Formal Charge	0

Physical & Chemical Properties

Melting Point	190-193ºC
LogP	2.2
Dissociation Constants	8.2

Physical description & handling notes

• Slightly soluble
• White to light yellow powder; slightly soluble in water /Dolutegravir sodium/
• Tivicay Tablets, 50 mg

Regulatory Status

GHS notification summary	33.3% (1 / 3)

GHS Hazard Classification

GHS notification summary	33.3% (1 / 3)
Reported hazard statements	H400 (66.7%), H410 (66.7%)

Documented Uses

• Preparation: B. A. Johns et al., World Intellectual Property Organization patent 06116764 (2006 to Shionogi); eidem, United States of America patent 090318421 (2009)
• Dolutegravir is a human immunodeficiency virus (HIV) integrase inhibitor, the third in this class of agents that target the viral integrase. Dolutegravir is used only in combination with other antiretroviral agents in the treatment of HIV infection, and it has had limited use. Dolutegravir is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of acute, clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Integrase Inhibitors
• Antiretrovirals > Integrase inhibitors
• Oral - Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
• Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Synonyms

Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; GSK 1349572; GSK-1349572; S-349572; DKO1W9H7M1; CHEBI:76010; DTXSID90909356; dolutegravirum; RefChem:56964; J05AX12; DTXCID701338419; Tivicay; Dolutegravir (GSK1349572)

Frequently Asked Questions

What are the CAS number and molecular formula of Dolutegravir?

CAS 1051375-16-6; molecular formula C20H19F2N3O5; molecular weight — g/mol.

What other names is Dolutegravir known by?

Dolutegravir, 1051375-16-6, GSK1349572, S/GSK1349572, GSK 1349572, GSK-1349572.

Is Dolutegravir classified as hazardous?

33.3% of GHS notifications report no hazard classification (1 of 3).

What are the key physical properties of Dolutegravir?

Melting Point: 190-193ºC; LogP: 2.2; Dissociation Constants: 8.2.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.